Puma's neratinib gets by in NSCLC, with a little help from Imodium
This article was originally published in Scrip
Puma Biotechnology's novel targeted anticancer neratinib appears to have found a new therapeutic setting on the basis of Phase II data presented at a late-breaking oral session at the recent ESMO meeting that suggest potential in non-small cell lung cancer.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.